{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:56:20Z","timestamp":1766087780170,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL154254","NS107461","NS109486"],"award-info":[{"award-number":["HL154254","NS107461","NS109486"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003187","name":"NSF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["EEC-1648035"],"award-info":[{"award-number":["EEC-1648035"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biomedical Engineering"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cobme.2021.100341","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T23:00:12Z","timestamp":1631660412000},"page":"100341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Integrating in\u00a0vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-4470","authenticated-orcid":false,"given":"Yunfeng","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric V.","family":"Shusta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Palecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cobme.2021.100341_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fncel.2019.00405","article-title":"The evolving concept of the blood brain barrier (BBB): from a single static barrier to a heterogeneous and dynamic relay center","volume":"13","author":"Villabona-Rueda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.cobme.2021.100341_bib2","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cobme.2021.100341_bib3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-180098","article-title":"Role of blood-brain barrier in Alzheimer's disease","volume":"63","author":"Cai","year":"2018","journal-title":"J.\u00a0Alzheimers. Dis."},{"key":"10.1016\/j.cobme.2021.100341_bib4","doi-asserted-by":"crossref","first-page":"593026","DOI":"10.3389\/fphys.2020.593026","article-title":"Blood-brain barrier leakage is increased in Parkinson's disease","volume":"11","author":"Al-Bachari","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.cobme.2021.100341_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.cobme.2021.100341_bib6","article-title":"In\u00a0vitro modeling of the neurovascular unit: advances in the field","volume":"vol. 17","author":"Bhalerao","year":"2020"},{"key":"10.1016\/j.cobme.2021.100341_bib7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/mp300570z","article-title":"Confounding parameters in preclinical assessment of blood\u2013brain barrier permeation: an overview with emphasis on species differences and effect of disease states","volume":"10","author":"Deo","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cobme.2021.100341_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cobme.2021.100341_bib9","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.cobme.2021.100341_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.cobme.2021.100341_bib11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/ph13110394","article-title":"Treatment of Alzheimer's disease and blood-brain barrier drug delivery","volume":"13","author":"Pardridge","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cobme.2021.100341_bib12","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3389\/fimmu.2018.03062","article-title":"Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy","volume":"9","author":"Chuntova","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cobme.2021.100341_sref13","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-019-0165-2","article-title":"Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in\u00a0vitro","volume":"17","author":"Nishihara","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.cobme.2021.100341_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.tibtech.2016.01.001","article-title":"Stem cell-based human blood-brain barrier models for drug discovery and delivery","volume":"34","author":"Aday","year":"2016","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.cobme.2021.100341_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cobme.2017.11.002","article-title":"Modeling the blood-brain barrier: beyond the endothelial cells","volume":"5","author":"Gastfriend","year":"2018","journal-title":"Curr Opin Biomed Eng"},{"key":"10.1016\/j.cobme.2021.100341_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coche.2020.07.002","article-title":"In\u00a0vitro models of the blood-brain barrier: building in physiological complexity","volume":"30","author":"Katt","year":"2020","journal-title":"Curr. Opin. Chem. Eng."},{"key":"10.1016\/j.cobme.2021.100341_sref17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.stem.2019.05.011","article-title":"Human iPSC-derived blood-brain barrier chips enable disease modeling and personalized medicine applications","volume":"24","author":"Vatine","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cobme.2021.100341_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15623","article-title":"Blood-brain-barrier spheroids as an in\u00a0vitro screening platform for brain-penetrating agents","volume":"8","author":"Cho","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cobme.2021.100341_sref19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41591-020-0886-4","article-title":"Reconstruction of the human blood-brain barrier in\u00a0vitro reveals a pathogenic mechanism of APOE4 in pericytes","volume":"26","author":"Blanchard","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.cobme.2021.100341_bib20","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1021\/acs.molpharmaceut.6b00818","article-title":"Minimum transendothelial electrical resistance thresholds for the study of small and large molecule drug transport in a human in\u00a0vitro blood\u2013brain barrier model","volume":"13","author":"Mantle","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cobme.2021.100341_bib21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.stemcr.2017.02.021","article-title":"Establishment of a human blood-brain barrier Co-culture model mimicking the neurovascular unit using induced pluri- and multipotent stem cells","volume":"8","author":"Appelt-Menzel","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.cobme.2021.100341_bib22","doi-asserted-by":"crossref","first-page":"16310","DOI":"10.1038\/s41598-019-52213-6","article-title":"Proof-of-concept study of drug brain permeability between in\u00a0vivo human brain and an in\u00a0vitro iPSCs-human blood-brain barrier model","volume":"9","author":"Roux","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cobme.2021.100341_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.nano.2011.05.004","article-title":"Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model","volume":"7","author":"Re","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cobme.2021.100341_sref24","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41598-020-60684-1","article-title":"Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages","volume":"10","author":"Gong","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cobme.2021.100341_bib25","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1039\/C9NR03931G","article-title":"Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in\u00a0vitro blood-brain barrier","volume":"11","author":"Shi","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.cobme.2021.100341_bib26","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/D0BM01726D","article-title":"H-Ferritin nanoparticle-mediated delivery of antibodies across a BBB in\u00a0vitro model for treatment of brain malignancies","volume":"9","author":"Rizzuto","year":"2021","journal-title":"Biomater Sci"},{"key":"10.1016\/j.cobme.2021.100341_bib27","doi-asserted-by":"crossref","first-page":"14582","DOI":"10.1038\/s41598-020-71286-2","article-title":"Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain","volume":"10","author":"Christensen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cobme.2021.100341_bib28","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1096\/fj.202000851R","article-title":"Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS","volume":"34","author":"Georgieva","year":"2020","journal-title":"Faseb J"},{"key":"10.1016\/j.cobme.2021.100341_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.cobme.2021.100341_bib30","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41598-018-19522-8","article-title":"A\u00a0novel human induced pluripotent stem cell blood-brain barrier model: applicability to study antibody-triggered receptor-mediated transcytosis","volume":"8","author":"Ribecco-Lutkiewicz","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cobme.2021.100341_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.cobme.2021.100341_bib32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cobme.2021.100341_sref33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.cobme.2021.100341_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/hum.2019.186","article-title":"Ly6a differential expression in blood-brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B","volume":"31","author":"Batista","year":"2020","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.cobme.2021.100341_bib35","doi-asserted-by":"crossref","first-page":"582979","DOI":"10.3389\/fbioe.2020.582979","article-title":"PHP.B\/eB vectors bring new successes to gene therapy for brain diseases","volume":"8","author":"Reynaud-Dulaurier","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.cobme.2021.100341_bib36","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","article-title":"AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy","volume":"25","author":"Morabito","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.cobme.2021.100341_bib37","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.cobme.2021.100341_bib38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The neurotropic properties of AAV-PHP.B are limited to C57bl\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.cobme.2021.100341_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.cobme.2021.100341_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cobme.2021.100341_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biomaterials.2018.05.041","article-title":"Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration","volume":"176","author":"Zhang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.cobme.2021.100341_bib42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.15252\/emmm.201506078","article-title":"A\u00a0brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases","volume":"8","author":"K\u00f6rbelin","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cobme.2021.100341_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12967-020-02598-0","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight","volume":"18","author":"Land","year":"2020","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.cobme.2021.100341_bib44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00702-005-0409-y","article-title":"Molecular mechanisms involved in T cell migration across the blood-brain barrier","volume":"113","author":"Engelhardt","year":"2006","journal-title":"J\u00a0Neural Transm (Vienna)"},{"key":"10.1016\/j.cobme.2021.100341_bib45","doi-asserted-by":"crossref","first-page":"16693","DOI":"10.1096\/fj.202001507RR","article-title":"Advancing human induced pluripotent stem cell-derived blood-brain barrier models for studying immune cell interactions","volume":"34","author":"Nishihara","year":"2020","journal-title":"Faseb J"},{"key":"10.1016\/j.cobme.2021.100341_bib46","doi-asserted-by":"crossref","first-page":"1900962","DOI":"10.1002\/advs.201900962","article-title":"Blood-brain barrier dysfunction in a 3D in\u00a0vitro model of Alzheimer's disease","volume":"6","author":"Shin","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.cobme.2021.100341_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2016.09.003","article-title":"\u03b1-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function","volume":"285","author":"Kuan","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cobme.2021.100341_bib48","article-title":"Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption in Parkinson's disease","author":"Pediaditakis","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.cobme.2021.100341_sref49","doi-asserted-by":"crossref","first-page":"105131","DOI":"10.1016\/j.nbd.2020.105131","article-title":"The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier","volume":"146","author":"Buzhdygan","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cobme.2021.100341_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12987-018-0100-y","article-title":"Zika virus crosses an in\u00a0vitro human blood brain barrier model","volume":"15","author":"Alimonti","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.cobme.2021.100341_bib51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.bcp.2013.03.022","article-title":"Transport of gabapentin by LAT1 (SLC7A5)","volume":"85","author":"Dickens","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cobme.2021.100341_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096340","article-title":"A\u00a0human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding","volume":"9","author":"Sade","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cobme.2021.100341_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fimmu.2019.00711","article-title":"PECAM-1 stabilizes blood-brain barrier integrity and favors paracellular T-cell diapedesis across the blood-brain barrier during neuroinflammation","volume":"10","author":"Wimmer","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cobme.2021.100341_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/jcbfm.2010.96","article-title":"Comparison of immortalized bEnd5 and primary mouse brain microvascular endothelial cells as in\u00a0vitro blood-brain barrier models for the study of T cell extravasation","volume":"31","author":"Steiner","year":"2011","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.cobme.2021.100341_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217216","article-title":"Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies","volume":"14","author":"Majerova","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.cobme.2021.100341_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.29595","article-title":"Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating highdensity lipoproteins in bioengineered human vessels","volume":"6","author":"Robert","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.cobme.2021.100341_bib57","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/bit.26967","article-title":"Immunoglobulin G transport increases in an in\u00a0vitro blood\u2013brain barrier model with amyloid-\u03b2 and with neuroinflammatory cytokines","volume":"116","author":"Mantle","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.cobme.2021.100341_bib58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jnc.13122","article-title":"A\u03b2(1-42) oligomer-induced leakage in an in\u00a0vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins","volume":"134","author":"Wan","year":"2015","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.cobme.2021.100341_bib59","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3233\/JAD-150976","article-title":"Modulation of amyloid-\u03b21-40 transport by ApoA1 and ApoJ across an in\u00a0vitro model of the blood-brain barrier","volume":"53","author":"Merino-Zamorano","year":"2016","journal-title":"J.\u00a0Alzheimers. Dis."},{"key":"10.1016\/j.cobme.2021.100341_bib60","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s11011-019-00447-8","article-title":"Amyloid Beta 25-35 induces blood-brain barrier disruption in\u00a0vitro","volume":"34","author":"Cuevas","year":"2019","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.cobme.2021.100341_bib61","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/jnr.23964","article-title":"Limitations of the hCMEC\/D3 cell line as a model for A\u03b2 clearance by the human blood-brain barrier","volume":"95","author":"Biemans","year":"2017","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.cobme.2021.100341_bib62","article-title":"P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson\u2019s disease candidate drug FLZ across the physiological and PD pathological in\u00a0vitro BBB models","volume":"9","author":"Liu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cobme.2021.100341_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mvr.2019.03.005","article-title":"Monomeric \u03b1-synuclein induces blood-brain barrier dysfunction through activated brain pericytes releasing inflammatory mediators in\u00a0vitro","volume":"124","author":"Dohgu","year":"2019","journal-title":"Microvasc Res"},{"key":"10.1016\/j.cobme.2021.100341_bib64","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41591-021-01443-1","article-title":"A human three-dimensional neural-perivascular \u2018assembloid\u2019 promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cobme.2021.100341_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fmicb.2020.00214","article-title":"The mechanism of the Zika virus crossing the placental barrier and the blood-brain barrier","volume":"11","author":"Chiu","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cobme.2021.100341_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102598","article-title":"West Nile virus-induced cell adhesion molecules on human brain microvascular endothelial cells regulate leukocyte adhesion and modulate permeability of the in\u00a0vitro blood-brain barrier model","volume":"9","author":"Roe","year":"2014","journal-title":"PloS One"}],"container-title":["Current Opinion in Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468451121000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468451121000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:02:59Z","timestamp":1762844579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468451121000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":66,"alternative-id":["S2468451121000817"],"URL":"https:\/\/doi.org\/10.1016\/j.cobme.2021.100341","relation":{},"ISSN":["2468-4511"],"issn-type":[{"type":"print","value":"2468-4511"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating in\u00a0vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biomedical Engineering","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cobme.2021.100341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100341"}}